Tests on new TB drugs have not yet been completed and some results have been worrying... Tuberculosis is a disease of the poor: today, 95% of global cases occur in low- and middle-income countries. Without a profit incentive, the impetus for companies to make new drugs is small, leaving patients and doctors with few good treatment options... “This is potentially revolutionary," says Gilles van Cutsem, medical co-ordinator for Doctors Without Borders (MSF) in South Africa and Lesotho. “To treat someone with more effective drugs, and faster, would radically change things."
Read article here